IGF-1 (Insulin-like Growth Factor 1) is a growth factor involved in various physiological processes, with studies in our corpus exploring its potential in preventing severe retinopathy in premature infants and as a treatment for Rett Syndrome. MK-677, an oral growth hormone secretagogue and ghrelin receptor agonist, primarily functions by stimulating the body's own growth hormone release, which in turn can increase IGF-1 levels. Evidence suggests MK-677 may enhance recovery in elderly hip fracture patients, boost lean body mass in healthy older adults, and increase IGF-1 levels in hemodialysis patients. Both peptides show promise in areas related to growth, metabolism, and age-related decline, often through modulation of the GH/IGF-1 axis.
| IGF-1 | MK-677 | |
|---|---|---|
| Drug class | growth factor | n/a |
| Studies in corpus | 109 | 96 |
| Highest evidence tier | meta analysis | rct |
| Evidence tier mix | cohort · 5 rct · 22 other · 27 case series · 1 meta analysis · 2 case report · 2 review · 12 preclinical animal · 27 in vitro · 6 | case report · 4 rct · 10 other · 20 preclinical animal · 29 in vitro · 15 review · 15 |
| Studies with explicit sample size | 10 | 2 |
| Head-to-head studies in corpus | 19 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real IGF-1 and MK-677 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 13 IGF-1 batches across 9 manufacturers, 99.16% avg purity.
We tested 29 MK-677 batches across 24 manufacturers, 98.15% avg purity.
We hold deeper lab coverage on MK-677 (29 batches tested). IGF-1 edges ahead on average measured purity (99.16% vs 98.15%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both IGF-1 and MK-677 — the gold-standard direct comparison evidence.
If the trial yielded positive results, this study would validate an oral therapeutic approach for fibromyalgia, potentially offering a more convenient and accessible alternative to injectable growth hormone. An effective oral treatment could significantly i…
This study provides compelling evidence that MK-0677, an oral growth hormone secretagogue, can significantly enhance recovery outcomes in elderly patients following hip fracture surgery. The observed improvements in lean body mass, muscle strength, and func…
This study provides compelling evidence that MK-0677, an oral ghrelin receptor agonist, can effectively increase IGF-1 levels in hemodialysis patients. This is a critical step towards addressing the IGF-1 deficiency often seen in this population, which cont…
This research highlights the potential of an oral ghrelin mimetic as a therapeutic strategy to combat age-related muscle loss and improve physical function in older adults. The oral route of administration offers a significant advantage over injectable ther…
This case report provides crucial, albeit preliminary, human data on the combined effects of LGD-4033 and MK-677, highlighting their potent impact on body composition and endocrine function. The observed anabolic effects (increased lean mass, decreased fat …
This research strongly suggests that targeting the GH/IGF-1 axis could be a powerful strategy to combat age-related cardiovascular decline and improve vascular health. By restoring endothelial progenitor cell (EPC) function, this approach could enhance the …
The development of GHSs represents a paradigm shift in treating conditions associated with GH deficiency or catabolic states. These compounds offer a non-invasive, orally active alternative to recombinant GH, potentially expanding access to anabolic therapi…
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the body's own GH release, offers a promising…
The findings suggest that GHS represent a promising therapeutic strategy for combating age-related decline in GH and IGF-1, potentially improving body composition and overall vitality in older adults. By stimulating endogenous GH production, GHS offer a mor…
This comprehensive review underscores the therapeutic promise of GHS for conditions characterized by GH deficiency or age-related decline, such as sarcopenia and frailty, by effectively stimulating endogenous GH release. The findings suggest that GHS could …
Direct head-to-head trials comparing IGF-1 and MK-677 are present in our corpus, with 19 such studies. While IGF-1 is a direct growth factor, MK-677 acts as a secretagogue, stimulating the body's endogenous production of growth hormone, which then leads to increased IGF-1 levels. For instance, one RCT demonstrated that MK-0677 effectively increased IGF-1 levels in hemodialysis patients. IGF-1 has been investigated as a potential treatment for Rett Syndrome in a Phase 2 trial and for preventing severe retinopathy in premature infants in meta-analyses. MK-677, being an oral compound, offers a potential advantage in terms of administration, with studies exploring its use in fibromyalgia, improving recovery in elderly hip fracture patients, and boosting lean mass in healthy older adults. Reviews also highlight GHSs like MK-677 as a non-invasive, orally active alternative to recombinant GH for conditions associated with GH deficiency or catabolic states, and for their impact on bone health.
Looking for vendor-level purity, endotoxin, and HPLC data on IGF-1 or MK-677? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.